Online inquiry

IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14849MR)

This product GTTS-WQ14849MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14849MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12797MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ15199MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ5927MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ5454MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDA 1
GTTS-WQ5880MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ3579MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ10853MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ5067MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CaCP-29
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW